RATIONALE: Basophils contribute to anaphylaxis and allergies. We examined the utility of assessing basophil-associated surface antigens (CD11b/CD63/CD123/CD203c/CD294) in characterizing and monitoring subjects with nut allergy. METHODS: We used flow cytometry to analyze basophils at baseline (without any activation) and after ex vivo stimulation of whole blood by addition of nut or other allergens for 2, 10, and 30 min. We also evaluated whether basophil expression of CD11b/CD63/CD123/CD203c/CD294 was altered in subjects treated with anti-IgE monoclonal antibody (omalizumab) to reduce plasma levels of IgE. RESULTS: We demonstrate that basophil CD203c levels are increased at baseline in subjects with nut allergy compared to healthy controls (13 subjects in each group, p < 0.0001). Furthermore, we confirm that significantly increased expression of CD203c occurs on subject basophils when stimulated with the allergen to which the subject is sensitive and can be detected rapidly (10 min of stimulation, n = 11, p < 0.0008). In 5 subjects with severe peanut allergy, basophil CD203c expression following stimulation with peanut allergen was significantly decreased (p < 0.05) after 4 and 8 weeks of omalizumab treatment but returned toward pretreatment levels after treatment cessation. CONCLUSIONS: Subjects with nut allergy show an increase of basophil CD203c levels at baseline and following rapid ex vivo stimulation with nut allergen. Both can be reduced by omalizumab therapy. These results highlight the potential of using basophil CD203c levels for baseline diagnosis and therapeutic monitoring in subjects with nut allergy.
RATIONALE: Basophils contribute to anaphylaxis and allergies. We examined the utility of assessing basophil-associated surface antigens (CD11b/CD63/CD123/CD203c/CD294) in characterizing and monitoring subjects with nut allergy. METHODS: We used flow cytometry to analyze basophils at baseline (without any activation) and after ex vivo stimulation of whole blood by addition of nut or other allergens for 2, 10, and 30 min. We also evaluated whether basophil expression of CD11b/CD63/CD123/CD203c/CD294 was altered in subjects treated with anti-IgE monoclonal antibody (omalizumab) to reduce plasma levels of IgE. RESULTS: We demonstrate that basophil CD203c levels are increased at baseline in subjects with nut allergy compared to healthy controls (13 subjects in each group, p < 0.0001). Furthermore, we confirm that significantly increased expression of CD203c occurs on subject basophils when stimulated with the allergen to which the subject is sensitive and can be detected rapidly (10 min of stimulation, n = 11, p < 0.0008). In 5 subjects with severe peanutallergy, basophil CD203c expression following stimulation with peanut allergen was significantly decreased (p < 0.05) after 4 and 8 weeks of omalizumab treatment but returned toward pretreatment levels after treatment cessation. CONCLUSIONS: Subjects with nut allergy show an increase of basophil CD203c levels at baseline and following rapid ex vivo stimulation with nut allergen. Both can be reduced by omalizumab therapy. These results highlight the potential of using basophil CD203c levels for baseline diagnosis and therapeutic monitoring in subjects with nut allergy.
Authors: Karen M Yasnowsky; Stephen C Dreskin; Benjamin Efaw; David Schoen; P K Vedanthan; Rafeul Alam; Ronald J Harbeck Journal: J Allergy Clin Immunol Date: 2006-04-27 Impact factor: 10.793
Authors: F E R Simons; A J Frew; I J Ansotegui; B S Bochner; D B K Golden; F D Finkelman; D Y M Leung; J Lotvall; G Marone; D D Metcalfe; U Müller; L J Rosenwasser; H A Sampson; L B Schwartz; M van Hage; A F Walls Journal: Allergy Date: 2008-01 Impact factor: 13.146
Authors: James W Tung; Kartoosh Heydari; Rabin Tirouvanziam; Bita Sahaf; David R Parks; Leonard A Herzenberg; Leonore A Herzenberg Journal: Clin Lab Med Date: 2007-09 Impact factor: 1.935
Authors: D W MacGlashan; B S Bochner; D C Adelman; P M Jardieu; A Togias; J McKenzie-White; S A Sterbinsky; R G Hamilton; L M Lichtenstein Journal: J Immunol Date: 1997-02-01 Impact factor: 5.422
Authors: Jörg Kleine-Tebbe; Stephan Erdmann; Edward F Knol; Donald W MacGlashan; Lars K Poulsen; Bernhard F Gibbs Journal: Int Arch Allergy Immunol Date: 2006-07-11 Impact factor: 2.749
Authors: John F Ryan; Rachel Hovde; Jacob Glanville; Shu-Chen Lyu; Xuhuai Ji; Sheena Gupta; Robert J Tibshirani; David C Jay; Scott D Boyd; R Sharon Chinthrajah; Mark M Davis; Stephen J Galli; Holden T Maecker; Kari C Nadeau Journal: Proc Natl Acad Sci U S A Date: 2016-01-25 Impact factor: 11.205
Authors: Emily C McGowan; Jessica H Savage; Jean-Paul Courneya; Patricia M Sterba; Saitu Parihar; Jing Lin; Gustavo Gimenez; Hugh A Sampson; John Schroeder; Donald MacGlashan; Robert A Wood; Robert G Hamilton; Sarbjit Saini Journal: J Allergy Clin Immunol Date: 2014-06-27 Impact factor: 10.793
Authors: Laurent L Reber; Thomas Marichal; Kaori Mukai; Yoshihiro Kita; Suzumi M Tokuoka; Axel Roers; Karin Hartmann; Hajime Karasuyama; Kari C Nadeau; Mindy Tsai; Stephen J Galli Journal: J Allergy Clin Immunol Date: 2013-08-01 Impact factor: 10.793
Authors: John T Schroeder; Anja P Bieneman; Kristin L Chichester; Corinne A Keet; Robert G Hamilton; Donald W MacGlashan; Robert Wood; Pamela A Frischmeyer-Guerrerio Journal: J Allergy Clin Immunol Date: 2013-10-17 Impact factor: 10.793
Authors: Sarfaraz Hasni; Sarthak Gupta; Michael Davis; Elaine Poncio; Yenealem Temesgen-Oyelakin; Elizabeth Joyal; Alice Fike; Zerai Manna; Sungyoung Auh; Yinghui Shi; Diana Chan; Philip Carlucci; Ann Biehl; Barbara Dema; Nicolas Charles; James E Balow; Meryl Waldman; Richard M Siegel; Mariana J Kaplan; Juan Rivera Journal: Arthritis Rheumatol Date: 2019-05-08 Impact factor: 10.995